Albendazole therapy for solitary persistent cysticercus granuloma
Related Experiment Video
Updated: Oct 8, 2026

Transient Transduction of the Strobilated Forms of Echinococcus granulosus
Published on: September 16, 2022
1Department of Neurology, Postgraduate Institute of Medical Education and Research, Chandigarh - 160012, India.
Abstract:
Use of Albendazole therapy for the treatment of patients having persisting intracranial solitary cysticercus granuloma is controversial. Most of the times these patients are treated empirically with variety of drugs for variable period. Some authors advocate biopsy before definitive treatment. 25 patients having radiologicaly persistent solitary cysticercus granuloma (>6 months) were given 15 days course of oral albendazole (15 mg/kg body wt). Cranial CT scan was repeated one month after the completion of albendazole therapy. It was evaluated for complete resolution, partial response (> 50% decrease in size of lesion) or no change as compared to previous scan. 12 patients (48%) showed complete resolution, 4 patients (16%) showed a partial response, while 9 patients (36%) did not show any change on follow up. Albendazole therapy may be useful for patients having persistent cysticercus granuloma.
Related Concept Videos
Anthelminthic Agents
Giardiasis
Amebiasis
Toxoplasmosis
American Trypanosomiasis
Antiprotozoal Agents
